Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Mar 30;57(3):239–253. doi: 10.1007/s13312-020-1759-0

Refractory and Super-refractory Status Epilepticus

Debopam Samanta 1, Lisa Garrity 2, Ravindra Arya 2,3,✉
PMCID: PMC7224023  PMID: 32198865

Abstract

Context

Refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE) are neurological emergencies with considerable mortality and morbidity. In this paper, we provide an overview of causes, evaluation, treatment, and consequences of RSE and SRSE, reflecting the lack of high-quality evidence to inform therapeutic approach.

Sources

This is a narrative review based on personal practice and experience. Nevertheless, we searched MEDLINE (using PubMed and OvidSP vendors) and Cochrane central register of controlled trials, using appropriate keywords to incorporate recent evidence.

Results

Refractory status epilepticus is commonly defined as an acute convulsive seizure that fails to respond to two or more anti-seizure medications including at least one nonbenzodiazepine drug. Super-refractory status epilepticus is a status epilepticus that continues for ≥24 hours despite anesthetic treatment, or recurs on an attempted wean of the anesthetic regimen. Both can occur in patients known to have epilepsy or de novo, with increasing recognition of autoimmune and genetic causes. Electroencephalography monitoring is essential to monitor treatment response in refractory/super-refractory status epilepticus, and to diagnose non-convulsive status epilepticus. The mainstay of treatment for these disorders includes anesthetic infusions, primarily midazolam, ketamine, and pentobarbital. Dietary, immunological, and surgical treatments are viable in selected patients. Management is challenging due to multiple acute complications and long-term adverse consequences.

Conclusions

We have provided a synopsis of best practices for diagnosis and management of refractory/superrefractory status epilepticus and highlighted the lack of sufficient high-quality evidence to drive decision making, ending with a brief foray into avenues for future research.

Keywords: Convulsive status epilepticus, Epilepsy, Management, Outcome

References

  • 1.Sanchez Fernandez I, Abend NS, Agadi S, An S, Arya R, Carpenter JL, et al. Gaps and opportunities in refractory status epilepticus research in children: A multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG) Seizure. 2014;23:87–97. doi: 10.1016/j.seizure.2013.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18. doi: 10.1093/brain/awr215. [DOI] [PubMed] [Google Scholar]
  • 3.Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:205–10. doi: 10.1001/archneur.59.2.205. [DOI] [PubMed] [Google Scholar]
  • 4.Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol. 2004;11:800–10. doi: 10.1111/j.1468-1331.2004.00943.x. [DOI] [PubMed] [Google Scholar]
  • 5.Shinnar S, Bello JA, Chan S, Hesdorffer DC, Lewis DV, Macfall J, et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology. 2012;79:871–7. doi: 10.1212/WNL.0b013e318266fcc5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lewis DV, Shinnar S, Hesdorffer DC, Bagiella E, Bello JA, Chan S, et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann Neurol. 2014;75:178–85. doi: 10.1002/ana.24081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hesdorffer DC, Shinnar S, Lewis DV, Nordli D Jr, Pellock JM, Moshe SL, et al. Risk factors for febrile status epilepticus: a case-control study. J Pediatr. 2013;163:1147–51. doi: 10.1016/j.jpeds.2013.05.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bassan H, Barzilay M, Shinnar S, Shorer Z, Matoth I, Gross-Tsur V. Prolonged febrile seizures, clinical characteristics, and acute management. Epilepsia. 2013;54:1092–8. doi: 10.1111/epi.12164. [DOI] [PubMed] [Google Scholar]
  • 9.Gulati S, Kalra V, Sridhar MR. Status epilepticus in Indian children in a tertiary care center. Indian J Pediatr. 2005;72:105–8. doi: 10.1007/BF02760691. [DOI] [PubMed] [Google Scholar]
  • 10.Sasidaran K, Singhi S, Singhi P. Management of acute seizure and status epilepticus in pediatric emergency. Indian J Pediatr. 2012;79:510–7. doi: 10.1007/s12098-011-0604-9. [DOI] [PubMed] [Google Scholar]
  • 11.Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: A randomized open-label study. Epilepsia. 2011;52:788–93. doi: 10.1111/j.1528-1167.2010.02949.x. [DOI] [PubMed] [Google Scholar]
  • 12.Misra UK, Kalita J. Seizures in encephalitis: predictors and outcome. Seizure. 2009;18:583–7. doi: 10.1016/j.seizure.2009.06.003. [DOI] [PubMed] [Google Scholar]
  • 13.Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314:144–9. doi: 10.1056/NEJM198601163140303. [DOI] [PubMed] [Google Scholar]
  • 14.Murthy JMK, Deshmukh DS. Convulsive status epilepticus due to different evolutionary stages of neurocysticercosis - solitary cyticercus granuloma, low cyst load, and single calcific lesion in an endemic country: Clinical profile. Seizure. 2019;71:229–32. doi: 10.1016/j.seizure.2019.07.012. [DOI] [PubMed] [Google Scholar]
  • 15.Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27:1460–9. doi: 10.1177/0883073812448838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Machado S, Pinto AN, Irani SR. What should you know about limbic encephalitis? Arq Neuropsiquiatr. 2012;70:817–22. doi: 10.1590/S0004-282X2012001000012. [DOI] [PubMed] [Google Scholar]
  • 18.Bhatnagar M, Shorvon S. Genetic mutations associated with status epilepticus. Epilepsy Behav. 2015;49:104–10. doi: 10.1016/j.yebeh.2015.04.013. [DOI] [PubMed] [Google Scholar]
  • 19.Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23. doi: 10.1007/s12028-012-9695-z. [DOI] [PubMed] [Google Scholar]
  • 20.Herman ST, Abend NS, Bleck TP, Chapman KE, Drislane FW, Emerson RG, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: Indications. J Clin Neurophysiol. 2015;32:87–95. doi: 10.1097/WNP.0000000000000166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Herman ST, Abend NS, Bleck TP, Chapman KE, Drislane FW, Emerson RG, et al. Consensus statement on continuous EEG in critically ill adults and children, part II: Personnel, technical specifications, and clinical practice. J Clin Neurophysiol. 2015;32:96–108. doi: 10.1097/WNP.0000000000000165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Leitinger M, Trinka E, Gardella E, Rohracher A, Kalss G, Qerama E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: A retrospective study. Lancet Neurol. 2016;15:1054–62. doi: 10.1016/S1474-4422(16)30137-5. [DOI] [PubMed] [Google Scholar]
  • 23.Beniczky S, Hirsch LJ, Kaplan PW, Pressler R, Bauer G, Aurlien H, et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia. 2013;54:28–9. doi: 10.1111/epi.12270. [DOI] [PubMed] [Google Scholar]
  • 24.Hirsch LJ, LaRoche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, et al. American Clinical Neurophysiology Society’s Standardized Critical Care EEG Terminology: 2012 version. J Clin Neurophysiol. 2013;30:1–27. doi: 10.1097/WNP.0b013e3182784729. [DOI] [PubMed] [Google Scholar]
  • 25.Sansevere AJ, Hahn CD, Abend NS. Conventional and quantitative EEG in status epilepticus. Seizure. 2019;68:38–45. doi: 10.1016/j.seizure.2018.09.011. [DOI] [PubMed] [Google Scholar]
  • 26.Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28. doi: 10.1093/brain/aws091. [DOI] [PubMed] [Google Scholar]
  • 27.Pearl PL, Vezina LG, Saneto RP, McCarter R, Molloy-Wells E, Heffron A, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50:184–94. doi: 10.1111/j.1528-1167.2008.01728.x. [DOI] [PubMed] [Google Scholar]
  • 28.Milh M, Villeneuve N, Chapon F, Pineau S, Lamoureux S, Livet MO, et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol. 2009;24:305–15. doi: 10.1177/0883073808324219. [DOI] [PubMed] [Google Scholar]
  • 29.Loscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia. 2007;48:74–7. doi: 10.1111/j.1528-1167.2007.01357.x. [DOI] [PubMed] [Google Scholar]
  • 30.Hocker S. Systemic complications of status epilepticus–An update. Epilepsy Behav. 2015;49:83–7. doi: 10.1016/j.yebeh.2015.04.024. [DOI] [PubMed] [Google Scholar]
  • 31.Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48–61. doi: 10.5698/1535-7597-16.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792–8. doi: 10.1056/NEJM199809173391202. [DOI] [PubMed] [Google Scholar]
  • 33.Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600. doi: 10.1056/NEJMoa1107494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014;311:1652–60. doi: 10.1001/jama.2014.2625. [DOI] [PubMed] [Google Scholar]
  • 35.Arya R, Kothari H, Zhang Z, Han B, Horn PS, Glauser TA. Efficacy of nonvenous medications for acute convulsive seizures: A network meta-analysis. Neurology. 2015;85:1859–68. doi: 10.1212/WNL.0000000000002142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.US Food and Drug Administrations. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf. Accessed July 31, 2019.
  • 37.Neuralis Inc. Our pipeline. https://www.neurelis.com/ourpipeline/valtoco-nasal-spray. Accessed July 31, 2019.
  • 38.French JA, Wechsler R, Gelfand MA, Pollard JR, Vazquez B, Friedman D, et al. Epilepsia. 2019. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. [DOI] [PubMed] [Google Scholar]
  • 39.Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies. Seizure. 2014;23:167–74. doi: 10.1016/j.seizure.2013.12.007. [DOI] [PubMed] [Google Scholar]
  • 40.Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): An open-label, multicentre, randomised controlled trial. Lancet. 2019;393:2135–45. doi: 10.1016/S0140-6736(19)30722-6. [DOI] [PubMed] [Google Scholar]
  • 41.Lyttle M R N, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): A multicentre, open-label, randomised trial. Lancet. 2019;393:2125–34. doi: 10.1016/S0140-6736(19)30724-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54:89–92. doi: 10.1111/epi.12288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14:4–10. doi: 10.1007/s12028-010-9445-z. [DOI] [PubMed] [Google Scholar]
  • 44.Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82:342–52. doi: 10.1002/ana.25008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: Literature review and a proposed protocol. Pediatr Neurol. 2008;38:377–90. doi: 10.1016/j.pediatrneurol.2008.01.001. [DOI] [PubMed] [Google Scholar]
  • 46.Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology. 2000;54:1366–8. doi: 10.1212/WNL.54.6.1366. [DOI] [PubMed] [Google Scholar]
  • 47.Gilbert DL, Gartside PS, Glauser TA. Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: A meta-analysis. J Child Neurol. 1999;14:602–9. doi: 10.1177/088307389901400909. [DOI] [PubMed] [Google Scholar]
  • 48.Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17:106–10. doi: 10.1177/088307380201700203. [DOI] [PubMed] [Google Scholar]
  • 49.Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med. 2006;32:2070–6. doi: 10.1007/s00134-006-0362-8. [DOI] [PubMed] [Google Scholar]
  • 50.Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review. Epilepsia. 2002;43:146–53. doi: 10.1046/j.1528-1157.2002.28501.x. [DOI] [PubMed] [Google Scholar]
  • 51.Kim SJ, Lee DY, Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. Pediatr Neurol. 2001;25:217–20. doi: 10.1016/S0887-8994(01)00311-3. [DOI] [PubMed] [Google Scholar]
  • 52.Holtkamp M, Masuhr F, Harms L, Einhaupl KM, Meierkord H, Buchheim K. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: A survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74:1095–9. doi: 10.1136/jnnp.74.8.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Bledsoe KA, Kramer AH. Propylene glycol toxicity complicating use of barbiturate coma. Neurocrit Care. 2008;9:122–4. doi: 10.1007/s12028-008-9065-z. [DOI] [PubMed] [Google Scholar]
  • 54.Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J. Propofol treatment of refractory status epilepticus: A study of 31 episodes. Epilepsia. 2004;45:757–63. doi: 10.1111/j.0013-9580.2004.01904.x. [DOI] [PubMed] [Google Scholar]
  • 55.Parviainen I, Uusaro A, Kalviainen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32:1075–9. doi: 10.1007/s00134-006-0154-1. [DOI] [PubMed] [Google Scholar]
  • 56.van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology. 2005;65:591–2. doi: 10.1212/01.wnl.0000173066.89001.f9. [DOI] [PubMed] [Google Scholar]
  • 57.McHugh P. Acute choreoathetoid reaction to propofol. Anaesthesia. 1991;46:425. doi: 10.1111/j.1365-2044.1991.tb09583.x. [DOI] [PubMed] [Google Scholar]
  • 58.Enting D, Ligtenberg JJ, Aarts LP, Zijlstra JG. Total suppression of cerebral activity by thiopental mimicking propofol infusion syndrome: A fatal common pathway? Anesth Analg. 2005;100:1864–5. doi: 10.1213/01.ANE.0000156682.59859.F3. [DOI] [PubMed] [Google Scholar]
  • 59.Baumeister FA, Oberhoffer R, Liebhaber GM, Kunkel J, Eberhardt J, Holthausen H, Peters J. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics. 2004;35:250–2. doi: 10.1055/s-2004-820992. [DOI] [PubMed] [Google Scholar]
  • 60.Hofler J, Trinka E. Intravenous ketamine in status epilepticus. Epilepsia. 2018;59:198–206. doi: 10.1111/epi.14480. [DOI] [PubMed] [Google Scholar]
  • 61.Keros S, Buraniqi E, Alex B, Antonetty A, Fialho H, Hafeez B, et al. Increasing ketamine use for refractory status epilepticus in US pediatric hospitals. J Child Neurol. 2017;32:638–46. doi: 10.1177/0883073817698629. [DOI] [PubMed] [Google Scholar]
  • 62.Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698–702. doi: 10.1001/archneur.62.11.1698. [DOI] [PubMed] [Google Scholar]
  • 63.An J, Jonnalagadda D, Moura VJ, Purdon PL, Brown EN, Westover MB. Variability in pharmacologically-induced coma for treatment of refractory status epilepticus. PLoS. One. 2018;13:e0205789. doi: 10.1371/journal.pone.0205789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Tasker RC, Goodkin H S, Fernandez I, Chapman KE, Abend NS, Arya R, et al. Refractory status epilepticus in children: Intention to treat with continuous infusions of midazolam and pentobarbital. Pediatr Crit Care Med. 2016;17:968–75. doi: 10.1097/PCC.0000000000000900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Alvarez V, Lee JW, Westover MB, Drislane FW, Novy J, Faouzi M, et al. Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study. Neurology. 2016;87:1650–9. doi: 10.1212/WNL.0000000000003224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656–64. doi: 10.1212/WNL.0000000000000009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Arya R, Rotenberg A. Dietary, immunological, surgical, and other emerging treatments for pediatric refractory status epilepticus. Seizure. 2019;68:89–96. doi: 10.1016/j.seizure.2018.09.002. [DOI] [PubMed] [Google Scholar]
  • 68.Likhodii SS, Serbanescu I, Cortez MA, Murphy P, Snead OC, 3rd, Burnham WM. Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet. Ann Neurol. 2003;54:219–26. doi: 10.1002/ana.10634. [DOI] [PubMed] [Google Scholar]
  • 69.Rho JM, Anderson GD, Donevan SD, White HS. Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia. 2002;43:358–61. doi: 10.1046/j.1528-1157.2002.47901.x. [DOI] [PubMed] [Google Scholar]
  • 70.Arya R, Peariso K G-, Lein M, Harvey J, Bergin A, Brenton JN, et al. Efficacy and safety of ketogenic diet for treatment of pediatric convulsive refractory status epilepticus. Epilepsy Res. 2018;144:1–6. doi: 10.1016/j.eplepsyres.2018.04.012. [DOI] [PubMed] [Google Scholar]
  • 71.Legriel S, Lemiale V, Schenck M, Chelly J, Laurent V, Daviaud F, et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med. 2016;375:2457–67. doi: 10.1056/NEJMoa1608193. [DOI] [PubMed] [Google Scholar]
  • 72.Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol. 2004;61:1254–9. doi: 10.1001/archneur.61.8.1254. [DOI] [PubMed] [Google Scholar]
  • 73.Fugate JE, Burns JD, Wijdicks EF, Warner DO, Jankowski CJ, Rabinstein AA. Prolonged high-dose isoflurane for refractory status epilepticus: is it safe? Anesth Analg. 2010;111:1520–4. doi: 10.1213/ANE.0b013e3181f6da34. [DOI] [PubMed] [Google Scholar]
  • 74.Ikeda KM, Connors R, Lee DH, Khandji AG, Claassen J, Young GB. Isoflurane use in the treatment of superrefractory status epilepticus is associated with hippocampal changes on MRI. Neurocrit Care. 2017;26:420–7. doi: 10.1007/s12028-016-0340-0. [DOI] [PubMed] [Google Scholar]
  • 75.Ferro MA, Chin RF, Camfield CS, Wiebe S, Levin SD, Speechley KN. Convulsive status epilepticus and healthrelated quality of life in children with epilepsy. Neurology. 2014;83:752–7. doi: 10.1212/WNL.0000000000000710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. Epilepsia. 2001;42:1461–7. doi: 10.1046/j.1528-1157.2001.21301.x. [DOI] [PubMed] [Google Scholar]
  • 77.Neligan A, Shorvon SD. Frequency and prognosis of convulsive status epilepticus of different causes: A systematic review. Arch Neurol. 2010;67:931–40. doi: 10.1001/archneurol.2010.169. [DOI] [PubMed] [Google Scholar]
  • 78.Pujar SS, Neville BG, Scott RC, Chin RF. North London Epilepsy Research N. Death within 8 years after childhood convulsive status epilepticus: a population-based study. Brain. 2011;134:2819–27. doi: 10.1093/brain/awr239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Pujar SS, Martinos MM, Cortina-Borja M C W D, Haan M, Gillberg C, et al. Long-term prognosis after childhood convulsive status epilepticus: A prospective cohort study. Lancet Child Adolesc Health. 2018;2:103–111. doi: 10.1016/S2352-4642(17)30174-8. [DOI] [PubMed] [Google Scholar]
  • 80.Sahin M, Menache CC, Holmes GL, Riviello JJ., Jr Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology. 2003;61:398–401. doi: 10.1212/01.WNL.0000073139.53008.F2. [DOI] [PubMed] [Google Scholar]
  • 81.Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989;83:323–31. [PubMed] [Google Scholar]
  • 82.Gurcharran K, Grinspan ZM. The burden of pediatric status epilepticus: Epidemiology, morbidity, mortality, and costs. Seizure. 2019;68:3–8. doi: 10.1016/j.seizure.2018.08.021. [DOI] [PubMed] [Google Scholar]
  • 83.Jafarpour S, Stredny CM, Piantino J, Chapman KE. Baseline and outcome assessment in pediatric status epilepticus. Seizure. 2019;68:52–61. doi: 10.1016/j.seizure.2018.04.019. [DOI] [PubMed] [Google Scholar]
  • 84.Martinos MM, Pujar S, Gillberg C, Cortina-Borja M N B, De Haan M, et al. Long-term behavioural outcomes after paediatric convulsive status epilepticus: A population-based cohort study. Dev Med Child Neurol. 2018;60:409–16. doi: 10.1111/dmcn.13636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029–35. doi: 10.1212/WNL.46.4.1029. [DOI] [PubMed] [Google Scholar]
  • 86.Sadarangani M, Seaton C, Scott JA, Ogutu B, Edwards T, Prins A, et al. Incidence and outcome of convulsive status epilepticus in Kenyan children: A cohort study. Lancet Neurol. 2008;7:145–50. doi: 10.1016/S1474-4422(07)70331-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Indian Pediatrics are provided here courtesy of Nature Publishing Group

RESOURCES